By Suherman Candra Maholtra 
New clinical data presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) reveals that adults with pre-existing heart disease who receive a shingles vaccine experience a 46% lower risk of major adverse cardiac events (MACE) within one year of vaccination compared to their unvaccinated counterparts. The findings, derived from a massive retrospective analysis of nearly a quarter-million patients, suggest that the herpes zoster vaccine may serve as a critical secondary preventive measure for individuals already diagnosed with atherosclerotic cardiovascular disease (ASCVD).
The study, led by Dr. Robert Nguyen of the University of California, Riverside, adds a significant layer to the evolving understanding of "immunocardiology"—a field exploring how vaccines against infectious diseases can mitigate the systemic inflammation that drives heart attacks and strokes. By preventing the reactivation of the varicella-zoster virus, which is known to cause vascular inflammation and blood clotting, the vaccine appears to provide a protective shield for the most vulnerable cardiac patients.
Understanding the Biological Link Between Shingles and Heart Risk
The relationship between shingles (herpes zoster) and cardiovascular health is rooted in the virus’s ability to affect the vascular system. Shingles is caused by the reactivation of the varicella-zoster virus, the same pathogen responsible for chickenpox. After an initial chickenpox infection, the virus remains dormant in the nerve tissues. As the immune system weakens with age or stress, the virus can reactivate, traveling along nerve fibers to the skin, resulting in a painful, blistering rash.
However, the impact of shingles extends far beyond the skin. Previous medical literature has established that during a shingles flare-up, the virus can cause significant inflammation in the blood vessels (vasculitis). This inflammation can lead to arterial stiffness and the potential rupture of atherosclerotic plaques—the fatty deposits that clog arteries in patients with heart disease. When these plaques rupture, they trigger the formation of blood clots, which can block blood flow to the brain (causing a stroke) or the heart (causing a myocardial infarction).
"Earlier research has shown that shingles infections can trigger blood clot formation near the brain and heart," the study authors noted. By preventing the viral reactivation in the first place, the vaccine effectively removes a potent inflammatory trigger, thereby stabilizing the cardiovascular system in high-risk patients.
Study Methodology and Patient Demographics
To quantify the cardioprotective effects of the vaccine, researchers utilized TriNetX, a global health research network that provides access to anonymized electronic medical records from millions of patients across the United States. The study focused on a specific high-risk cohort: adults aged 50 and older who had already been diagnosed with atherosclerotic heart disease between 2018 and 2025.
The research team identified 123,411 individuals who had received at least one dose of a shingles vaccine—either the older live-attenuated Zostavax or the newer, more common recombinant Shingrix vaccine. This group was then compared to a control group of 123,411 unvaccinated individuals. To ensure the validity of the results, the researchers employed propensity score matching, a statistical technique that balances the two groups based on age, gender, race, and various comorbidities, such as hypertension, diabetes, and chronic kidney disease.
The analysis specifically tracked outcomes starting one month after vaccination and continuing for one year. This "buffer month" was designed to ensure that any immediate post-vaccination inflammatory responses did not skew the data, focusing instead on the sustained protective window.
Comprehensive Risk Reduction Data
The results of the analysis showed a broad and significant reduction in nearly every category of cardiovascular event measured. Vaccinated individuals demonstrated a remarkably lower incidence of complications compared to those who did not receive the shot:
- Major Adverse Cardiac Events (MACE): The primary endpoint of the study, which includes a composite of heart attack, stroke, and death, was reduced by 46%.
- All-Cause Mortality: Vaccinated patients were 66% less likely to die from any cause during the one-year follow-up period.
- Heart Attack (Myocardial Infarction): The risk of a heart attack dropped by 32%.
- Stroke: The risk of ischemic or hemorrhagic stroke was reduced by 25%.
- Heart Failure: Vaccinated individuals saw a 25% lower risk of new or worsening heart failure.
Dr. Robert Nguyen emphasized the magnitude of these statistics during his presentation. "These reductions are substantial and comparable to the benefits seen from quitting smoking or starting a high-intensity statin regimen," Nguyen said. "Looking at the highest risk population—those with existing cardiovascular disease—these protective effects might be even greater than among the general public."
Historical Context and the Evolution of Shingles Vaccination
The findings presented at ACC.26 build upon a decade of research into the systemic benefits of adult immunizations. For years, the annual influenza vaccine has been recommended not just to prevent the flu, but as a standard component of post-heart attack care because of its proven ability to reduce secondary cardiac events.
The shingles vaccine is now following a similar trajectory. In 2022, a study published in the Journal of the American Heart Association suggested that shingles was associated with an 80% higher risk of stroke for up to a year after the infection. Furthermore, a 2025 study indicated that shingles vaccination was linked to a 23% reduction in cardiovascular events in generally healthy adults, with benefits potentially lasting up to eight years. The current study is unique because it focuses specifically on the "secondary prevention" group—those who are already ill—proving that the vaccine is effective even when the cardiovascular system is already compromised.
The shift in vaccine technology has also played a role. While the live-attenuated Zostavax was the standard for years, the introduction of Shingrix (a recombinant, adjuvanted vaccine) in 2017 provided much higher efficacy rates in preventing shingles (over 90%). The potent immune response triggered by Shingrix may be a contributing factor to the robust cardiovascular protection observed in the TriNetX data.
Public Health Implications and Clinical Recommendations
The Centers for Disease Control and Prevention (CDC) currently recommends two doses of the recombinant shingles vaccine for adults aged 50 and older, as well as for adults 19 and older who have weakened immune systems. Despite these recommendations, uptake remains inconsistent, often hindered by a lack of awareness or general vaccine hesitancy.
"Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen stated. "Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine."
For cardiologists, these findings suggest that the shingles vaccine should perhaps be viewed through the same lens as blood pressure medication or cholesterol-lowering drugs. If a single vaccine series can cut the risk of death by more than half in a high-risk population, it becomes a high-value clinical intervention. The study encourages a multidisciplinary approach where cardiologists and primary care physicians work together to ensure heart patients are up to date on their immunizations as part of a comprehensive "heart-healthy" lifestyle.
Addressing Study Limitations and Healthy User Bias
While the data is compelling, researchers acknowledged certain limitations inherent in observational studies. One significant factor is "healthy user bias"—the possibility that individuals who proactively seek out vaccinations are also more likely to exercise, eat a balanced diet, and adhere to their other cardiac medications.
To mitigate this, the researchers adjusted for socioeconomic factors, including housing stability, employment status, and education levels. However, they admitted that a retrospective review of medical records cannot fully account for all lifestyle variables.
"While we adjusted for several health and socioeconomic factors, it is still possible that some of the observed benefit is influenced by these differences," the research team noted. Nevertheless, the sheer size of the sample—over 240,000 people—and the consistency of the risk reduction across all categories of heart disease provide strong evidence of a direct correlation.
The study also only followed patients for one year. Future research will be required to determine if the 46% reduction in heart events persists over five or ten years, or if "booster" effects are necessary to maintain cardioprotection.
Future Directions in Immunocardiology
The presentation of this study at ACC.26 marks a pivotal moment in preventive cardiology. As the medical community continues to explore the inflammatory roots of heart disease, vaccines are emerging as a novel "anti-inflammatory" therapy.
Beyond shingles and influenza, researchers are also investigating the cardiac benefits of the pneumococcal vaccine and the potential long-term heart risks associated with COVID-19. The overarching theme is clear: preventing infectious diseases is a fundamental component of maintaining vascular health.
Dr. Nguyen will present the full details of the study, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30, at the American College of Cardiology’s Annual Scientific Session. The session is expected to draw significant attention from global health experts looking for cost-effective ways to reduce the burden of heart disease, which remains the leading cause of death worldwide.
As clinical guidelines continue to evolve, the shingles vaccine may soon transition from a "recommended" shot for the elderly to a "mandatory" intervention for anyone living with heart disease. For now, the message to patients is simple: protecting yourself from a painful rash might just save your life from a heart attack.
